ROLE OF COMPONENTS OF microRNA MACHINERY IN CARCINOGENESIS

Kian, R; Moradi, Siavash; Ghorbian, Saeid

doi:10.31768/2312-8852.2018.40(1):2-9

Cited by 37 publications

(30 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the human genome, miRNAs regulate protein encoding genes at a rate of approximately 1:3, controlling cell apoptosis, proliferation, differentiation, metabolism, individual development and tumorigenesis, and drug resistance. [14][15][16] Target gene expression is regulated by two mechanisms: (i) binding to the untranslated region (3'UTR) of the target messenger RNA (mRNA) 3' end, inhibiting its translation; and (ii) like small interfering RNA (siRNA), miRNA binds to the target and degrades target mRNA. [17][18][19] Recent studies have found that miRNAs regulate drug resistance by mediating their targeting genes in various cancers.…”

Section: Introductionmentioning

confidence: 99%

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Jin

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe five‐year survival rate of non‐small cell lung cancer (NSCLC) patients is very low. MiR‐873 is involved in the growth, metastasis, and differentiation of tumors. Herein, we determined the target gene and influence of miR‐873 in NSCLC.MethodsMiRanda and Targetscan websites were used to predict the target gene of miR‐873 in NSCLC. Luciferase activity was examined using a dual luciferase reporter gene assay kit. The viability, tube formation, and proliferation of cells were analyzed by cell counting kit‐8, angiogenic analysis, and flow cytometry, respectively. The levels of miR‐873 and GLI1 were evaluated using quantitative real‐time PCR and Western blot assays.ResultsLow levels of GLI1 and high levels of miR‐873 were observed in an NSCLC cell line (PC9) highly sensitive to EGFR‐tyrosine kinase inhibitors. There was a negative correlation between miR‐873 and GLI1 expression in PC9 and PC9/GR cells. The inhibition of miR‐873 enhanced GLI1 levels. MiR‐873 expression was inhibited by gefitinib. Gefitinib markedly reduced the viability, tube formation, and cell number in PC9 cells. However, suppression of miR‐873 enhanced the resistance and knockdown of GLI1 enhanced the sensitivity of PC9 cells to gefitinib.Conclusions GLI1 is a target gene of miR‐873 in NSCLC. The inhibition of miR‐873 increased gefitinib resistance of NSCLC cells via the upregulation of GLI1. These results indicate that miR‐873‐GLI1 signaling is involved in gefitinib resistance in NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

Jin

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Novel approaches in Rcc diagnosis and treatment are required. miRs have been reported to be involved in a number of biological processes of tumorigenesis (6), and miR replacement therapy has been considered to be promising in cancer treatment (14).…”

Section: Discussionmentioning

confidence: 99%

“…MicroRNAs (miRs) are a class of small non-coding RNAs that suppress gene expression by binding to the 3'-untranslated region of mRNA at the post-transcriptional level (5). Accumulating evidence suggested that miRs may be important in the development of malignancies (6). Previous studies demonstrated that miRs are involved in a number of cancer cell biological processes, including metastasis (7), invasion (8), angiogenesis (9), proliferation, apoptosis (10), differentiation (11), metabolism (12) and drug resistance (13).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑222‑3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with�an�unfavorable prognosis of patients with renal cell carcinoma

Zhao

Quan

et al. 2018

Int J Mol Med

View full text Add to dashboard Cite

The aim of the present study was to investigate the role of microRNA (miR)-222-3p in renal cell carcinoma (Rcc). The expression level of miR-222-3p was detected in Rcc tissues and cell lines (AcHN, 786-O, caki-1 and 769-P) and was identified to be significantly upregulated compared with the level in adjacent normal renal tissues and HK-2 cells. Further in vitro experiments demonstrated that the over expression of miR-222-3p promoted the migration and invasion, and attenuated the apoptosis of 786-O cells, whereas the knockdown of miR-222-3p suppressed the migration and invasion and induced the apoptosis of 786-O cells. Similar results were observed in the ACHN cell line in terms of migration, invasion and apoptosis. Furthermore, the expression level of miR-222-3p was measured in 42 RCC formaldehyde-fixed paraffin-embedded samples, and the association between the expression of miR-222-3p and the pathological characteristics and overall survival rate of patients with Rcc was analyzed. The results demonstrated that patients with a higher expression of miR-222-3p had a significantly lower overall survival rate, compared with those with a lower expression of miR-222-3p [hazard ratio (HR)=5.120; P=0.036]. Multivariate analysis identified that patients with a higher expression of miR-222-3p retained the statistically significant decrease in overall survival rate compared with patients with a lower expression of miR-222-3p (HR=5.636; P=0.030). Furthermore, Kaplan-Meier survival curves indicated that patients with higher miR-222-3p had significantly lower overall survival rates compared with patients with lower miR-222-3p (P=0.020). Taken together, these results suggested that miR-222-3p serves as an onco-miR in RCC and may be a potential prognostic biomarker and therapeutic target in patients with RCC.

show abstract

“…Therefore, it is not surprising that aberrant miRNA expression is involved in the pathogenesis of many diseases including cardiovascular diseases, neurodegenerative diseases, hematologic diseases, osteologic diseases and cancer. To this day, more than 2,650 different microRNAs have been described in various documents [2][3][4][5][6][7][8][9][10][11][12] .…”

Section: Introductionmentioning

confidence: 99%

“…In addition to the intracellular occurrence, micro-RNAs were also detected in the extracellular area -in the blood and its derivatives (plasma, serum), but also in the urine, saliva and other body fluids 5,6 . It has been proven that levels of circulating microRNAs are not random and reflect the events occurring within the organism/body.…”

Section: Introductionmentioning

confidence: 99%

Comparison of a new immunoassay and PCR-based method for quantification of microRNAs in whole blood. A pilot methodical study

Stejskal¹,

Hlozankova²,

Šigutová³

et al. 2019

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. MicroRNAs (miRNAs) are new generation biomarkers used in oncology, cardiology, metabolic syndrome, obesity or in neurology. miRNAs are short non-coding RNA molecules that regulate gene expression in eukaryotes. Aim. To compare a new commercial method for establishing miRNA (imunoassay) with a commercial kit RT qPCR. Methods. RNA was isolated from whole blood samples obtained from four healthy volunteers. The isolates were liquated and miRNA-93-5p and miRNA-23a-3p were measured independently with commercial hsa-miR-93-5p miREIA and hsa-miR-23a-3p miREIA, and commercial RT-qPCR kits. Results. Both miRNAs had good analytical characteristics, very good correlation with RT qPCR. The results between immunoassay and RT qPCR did not statistically differ. A method based on ELISA was faster (2 h with ELISA vs. 3 h with qPCR) and had lower CV then a method based on RT qPCR (see more text). Conclusion. MicroRNAs from blood or derived fractions are particularly interesting candidates for routine laboratory applications. The immunoassay can be performed on any device that processes the ELISA plates and is therefore available in almost every laboratory.

show abstract

ROLE OF COMPONENTS OF microRNA MACHINERY IN CARCINOGENESIS

Cited by 37 publications

References 51 publications

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1

MicroRNA‑222‑3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with�an�unfavorable prognosis of patients with renal cell carcinoma

Comparison of a new immunoassay and PCR-based method for quantification of microRNAs in whole blood. A pilot methodical study

Contact Info

Product

Resources

About